100 likes | 115 Views
This proposal aims to address the decline in pancreas transplants, particularly pancreas after kidney (PAK) transplants, which are underutilized. It suggests providing a guidance document with evidence in support of offering PAK transplants as an alternative to simultaneous pancreas and kidney (SPK) transplants, especially if the SPK waiting time exceeds one year. The implementation of this proposal would involve transplant hospitals using the guidance document as a resource and the OPTN committee monitoring and reviewing the number of PAKs performed annually.
E N D
Guidance on the Benefits of Pancreas After Kidney (PAK) Transplantation Pancreas Transplantation Committee
What problem will the proposal solve? • Decline in pancreas transplants, and substantial decline in PAKs Stratta, Robert J., Jonathan A. Fridell, Angelika C. Gruessner, Jon S. Odorico, and Rainer W.g. Gruessner. Pancreas transplantation: A Decade of Decline. Current Opinion in Organ Transplantation 21, no. 4 (August 2016): 386-92. doi:10.1097/mot.0000000000000319.
What problem will the proposal solve? • PAKs are underutilized: • Many uremic diabetic patients who receive a kidney transplant are not offered a subsequent pancreas transplant and miss the potential benefits: • PAK transplant recipients have survival advantage to SPK waiting list candidates • Receiving a pancreas after a kidney increases kidney graft survival • 2003 JAMA paper • Compared PAK patient survival to uremic diabetic patients waiting for a PAK who received a kidney alone, not to SPK waitlist candidate survival (as in current analysis)
What are the proposed solutions? • Provide a guidance document with evidence in support of offering PAK transplants • Guidance document recommends PAK transplantation as an alternative to SPK transplants for diabetic uremic candidates, particularly if the SPK waiting time is > 1 year
Data Analysis • Cohort: 28699 SPK, PTA, PAK candidates/recipients from 1995-2010 • Allows for long term follow up • larger cohort than 2003 JAMA paper • Does not exclude patients with reported creatinine > 2 mg/dl • Contrast with 2003 JAMA paper, which did exclude these patients • Analysis examined: • Kidney and pancreas graft survival across transplant type • Waitlist and recipient mortality by PAK, SPK • Hazard ratio of SPK and PAK patient recipient survival compared to SPK WL survival
How will members implement this proposal? • Transplant hospitals may use this guidance as a resource for staff, for discussions with patients and when considering organ offers • Guidance documents are for voluntary use by members and are not prescriptive of clinical practice
How will the OPTN implement this proposal? • Anticipated Board date: December 3-5, 2017 • Committee will monitor and annually review the number of PAKs performed • UNOS will create an educational component on how to use the guidance
Questions? Jon Odorico, MD Committee Chair jon@surgery.wisc.edu Abigail Fox, MPA Committee Liaison Abigail.fox@unos.org